Centiva Capital LP Sells 7,458 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Centiva Capital LP cut its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 24.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,490 shares of the company’s stock after selling 7,458 shares during the period. Centiva Capital LP’s holdings in Harmony Biosciences were worth $900,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Erste Asset Management GmbH bought a new stake in shares of Harmony Biosciences during the third quarter worth approximately $513,000. Verition Fund Management LLC raised its position in shares of Harmony Biosciences by 168.8% during the 3rd quarter. Verition Fund Management LLC now owns 54,976 shares of the company’s stock valued at $2,199,000 after acquiring an additional 34,524 shares during the last quarter. Martingale Asset Management L P lifted its stake in shares of Harmony Biosciences by 75.3% in the 3rd quarter. Martingale Asset Management L P now owns 34,783 shares of the company’s stock valued at $1,391,000 after purchasing an additional 14,946 shares during the period. Quantbot Technologies LP bought a new position in shares of Harmony Biosciences in the 3rd quarter worth $74,000. Finally, StoneX Group Inc. bought a new position in shares of Harmony Biosciences in the 3rd quarter worth $755,000. Institutional investors own 86.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on HRMY shares. Mizuho increased their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. UBS Group began coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target on the stock. Cantor Fitzgerald boosted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Tuesday, October 29th. Finally, Raymond James reissued an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Harmony Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

Harmony Biosciences Trading Down 4.1 %

HRMY opened at $33.49 on Friday. The stock has a market capitalization of $1.91 billion, a P/E ratio of 15.87, a P/E/G ratio of 0.64 and a beta of 0.79. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The firm’s fifty day simple moving average is $34.85 and its 200 day simple moving average is $33.83.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. During the same period in the prior year, the firm earned $0.63 earnings per share. Harmony Biosciences’s revenue for the quarter was up 16.0% compared to the same quarter last year. As a group, research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current fiscal year.

Insider Transactions at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 21,496 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 30.80% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.